|
1
|
Gacche RN and Meshram RJ: Targeting tumor
micro-environment for design and development of novel
anti-angiogenic agents arresting tumor growth. Prog Biophys Mol
Biol. 113:333–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wietecha MS, Cerny WL and DiPietro LA:
Mechanisms of vessel regression: toward an understanding of the
resolution of angiogenesis. Curr Top Microbiol Immunol. 367:3–32.
2013.PubMed/NCBI
|
|
3
|
Zhang Y, Yu LK, Lu GJ, Xia N, Xie HY, Hu
W, Hao KK, Xu CH and Qian Q: Prognostic values of VEGF and
endostatin with malignant pleural effusions in patients with lung
cancer. Asian Pac J Cancer Prev. 15:8435–8440. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yao X, Qian CN, Zhang ZF, Tan MH, Kort EJ,
Yang XJ, Resau JH and Teh BT: Two distinct types of blood vessels
in clear cell renal cell carcinoma have contrasting prognostic
implications. Clin Cancer Res. 13:161–169. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qi L, Du J, Zhang Z, Diao L, Chen X and
Yao X: Low differentiated microvascular density and low expression
of platelet-derived growth factor-BB (PDGF-BB) predict distant
metastasis and poor prognosis in clear cell renal cell carcinoma.
BJU Int. 112:E415–E423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fontanella C, Ongaro E, Bolzonello S,
Guardascione M, Fasola G and Aprile G: Clinical advances in the
development of novel VEGFR2 inhibitors. Ann Transl Med.
2:1232014.PubMed/NCBI
|
|
7
|
Welti J, Loges S, Dimmeler S and Carmeliet
P: Recent molecular discoveries in angiogenesis and antiangiogenic
therapies in cancer. J Clin Invest. 123:3190–3200. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jain RK: Antiangiogenesis strategies
revisited: from starving tumors to alleviating hypoxia. Cancer
Cell. 26:605–622. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
O'Reilly MS, Boehm T, Shing Y, Fukai N,
Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J:
Endostatin: an endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jain RK: Normalization of tumor
vasculature: an emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang Y, Yuan J, Righi E, Kamoun WS,
Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR,
Vianello F, et al: Vascular normalizing doses of antiangiogenic
treatment reprogram the immunosuppressive tumor microenvironment
and enhance immunotherapy. Proc Natl Acad Sci USA. 109:17561–17566.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang G and Chen L: Recombinant human
endostatin improves anti-tumor efficacy of paclitaxel by
normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res
Clin Oncol. 136:1201–1211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Giatromanolaki A, Koukourakis MI,
Theodossiou D, Barbatis K, O'Byrne K, Harris AL and Gatter KC:
Comparative evaluation of angiogenesis assessment with
anti-factor-VIII and anti-CD31 immunostaining in non-small cell
lung cancer. Clin Cancer Res. 3:2485–2492. 1997.PubMed/NCBI
|
|
14
|
Caraffi S, Corradi D, Campanini N, Govoni
P, Rocchi L, Perris R and Mangieri D: Microcirculation density and
maturity in uterine and soft tissue leiomyosarcomas: an
immunohistochemical study. Histol Histopathol. 30:69–76.
2015.PubMed/NCBI
|
|
15
|
Suster S and Wong TY: On the
discriminatory value of anti-HPCA-1 (CD-34) in the differential
diagnosis of benign and malignant cutaneous vascular
proliferations. Am J Dermatopathol. 16:355–363. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miyata Y, Mitsunari K, Asai A, Takehara K,
Mochizuki Y and Sakai H: Pathological significance and prognostic
role of microvessel density, evaluated using CD31, CD34, and CD105
in prostate cancer patients after radical prostatectomy with
neoadjuvant therapy. Prostate. 75:84–91. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fukumura D, Duda DG, Munn LL and Jain RK:
Tumor microvasculature and microenvironment: novel insights through
intravital imaging in pre-clinical models. Microcirculation.
17:206–225. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Poblet E, Gonzalez-Palacios F and Jimenez
FJ: Different immunoreactivity of endothelial markers in well and
poorly differentiated areas of angiosarcomas. Virchows Arch.
428:217–221. 1996.PubMed/NCBI
|
|
19
|
Barczyk M, Carracedo S and Gullberg D:
Integrins. Cell. 339:269–280. 2010.
|
|
20
|
Dong XP, Xiao TH, Dong H, Jiang N and Zhao
XG: Endostar combined with cisplatin inhibits tumor growth and
lymphatic metastasis of lewis lung carcinoma xenografts in mice.
Asian Pac J Cancer Prev. 14:3079–3083. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiao L, Yang S, Hao J, Yuan X, Luo W,
Jiang L, Hu Y, Fu Z, Zhang Y and Zou C: Endostar attenuates
melanoma tumor growth via its interruption of b-FGF mediated
angiogenesis. Cancer Lett. 359:148–154. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peng F, Xu Z, Wang J, Chen Y, Li Q, Zuo Y,
Chen J, Hu X, Zhou Q, Wang Y, et al: Recombinant human endostatin
normalizes tumor vasculature and enhances radiation response in
xenografted human nasopharyngeal carcinoma models. PLoS One.
7:e346462012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tong RT, Boucher Y, Kozin SV, Winkler F,
Hicklin DJ and Jain RK: Vascular normalization by vascular
endothelial growth factor receptor 2 blockade induces a pressure
gradient across the vasculature and improves drug penetration in
tumors. Cancer Res. 64:3731–3736. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
von Baumgarten L, Brucker D, Tirniceru A,
Kienast Y, Grau S, Burgold S, Herms J and Winkler F: Bevacizumab
has differential and dose-dependent effects on glioma blood vessels
and tumor cells. Clin Cancer Res. 17:6192–6205. 2011. View Article : Google Scholar : PubMed/NCBI
|
